Researcher.Life Logo

Expert Review of Pharmacoeconomics and Outcomes Research : Impact Factor & More

eISSN: 1744-8379pISSN: 1473-7167

Aims and Scope of Expert Review of Pharmacoeconomics and Outcomes Research

Expert Review of Pharmacoeconomics & Outcomes Research is a bimonthly peer-reviewed medical journal covering all aspects of pharmacoeconomics. It was established in 2001 and is published by Informa. The editor-in-chief is A. Bottomley (European Organisation for Research and Treatment of Cancer). Less

Key Metrics

CiteScore
3.4
H-Index
60
Impact Factor
< 5
SJR
Q2Health Policy
SNIP
0.9
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Expert Review of Pharmacoeconomics and Outcomes Research

Expert Review of Pharmacoeconomics and Outcomes Research Journal Specifications

Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year2001
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Expert Review of Pharmacoeconomics and Outcomes Research ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Expert Review of Pharmacoeconomics and Outcomes Research

Estimating respiratory syncytial virus health utility values for older adults and their caregivers in the Japanese population: a time trade-off study
  • 17 May 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Analyzing the direct medical cost of schizophrenia in Hospital Pulau Pinang, Malaysia
  • 16 May 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
The relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark, 2005–2019
  • 3 May 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB–IIC melanoma in the United States
  • 26 Apr 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Cost and clinical analysis of community-acquired pneumonia within an antimicrobial stewardship-governed academic hospital in South Africa, and its implications
  • 23 Apr 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Physicians’ preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in China
  • 21 Apr 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Estimating respiratory syncytial virus health utility values for older adults and their caregivers in the Japanese population: a time trade-off study
  • 17 May 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Analyzing the direct medical cost of schizophrenia in Hospital Pulau Pinang, Malaysia
  • 16 May 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
The relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark, 2005–2019
  • 3 May 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB–IIC melanoma in the United States
  • 26 Apr 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Cost and clinical analysis of community-acquired pneumonia within an antimicrobial stewardship-governed academic hospital in South Africa, and its implications
  • 23 Apr 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research
Physicians’ preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in China
  • 21 Apr 2026
  • Expert Review of Pharmacoeconomics & Outcomes Research

FAQs on Expert Review of Pharmacoeconomics and Outcomes Research